EDITORIAL
Published on 22 Aug 2022
Editorial: Disease modifying therapies in multiple sclerosis
doi 10.3389/fneur.2022.927321
- 1,307 views
- Frontiers in Neurology
- Multiple Sclerosis and Neuroimmunology
- Research Topics
- Disease Modifying Therapies in Multiple Sclerosis
Disease Modifying Therapies in Multiple Sclerosis
29k
Total downloads
138k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 06 Jun 2022
Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation
doi 10.3389/fimmu.2022.678817
- 5,189 views
- 2 citations
CASE REPORT
Published on 08 Dec 2021
Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Report
doi 10.3389/fneur.2021.664596
- 1,622 views
- 3 citations
POLICY AND PRACTICE REVIEWS
Published on 21 Oct 2021
Clinical Pathway for the Diagnosis and Management of Patients With Relapsing–Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population
doi 10.3389/fneur.2021.667398
- 3,660 views
- 1 citation
CASE REPORT
Published on 20 Oct 2021
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series
doi 10.3389/fneur.2021.691616
- 4,407 views
- 1 citation
ORIGINAL RESEARCH
Published on 07 Sep 2021
Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation
doi 10.3389/fneur.2021.659678
- 2,341 views
- 8 citations
ORIGINAL RESEARCH
Published on 01 Sep 2021
The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility
doi 10.3389/fneur.2021.679355
- 2,863 views
- 3 citations
ORIGINAL RESEARCH
Published on 26 Aug 2021
Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing–Remitting Multiple Sclerosis Treated With Dimethylfumarate
doi 10.3389/fneur.2021.683398
- 2,356 views
- 6 citations
ORIGINAL RESEARCH
Published on 23 Aug 2021
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
doi 10.3389/fneur.2021.699844
- 3,243 views
- 9 citations
REVIEW
Published on 20 Aug 2021
The Role of Distinct Subsets of Macrophages in the Pathogenesis of MS and the Impact of Different Therapeutic Agents on These Populations
doi 10.3389/fimmu.2021.667705
- 4,913 views
- 22 citations
ORIGINAL RESEARCH
Published on 05 Aug 2021
Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
doi 10.3389/fneur.2021.620758
- 4,317 views
- 8 citations
REVIEW
Published on 28 Jul 2021
Review: The Nutritional Management of Multiple Sclerosis With Propionate
doi 10.3389/fimmu.2021.676016
- 7,076 views
- 12 citations
Published in
Frontiers in Neurology
- Multiple Sclerosis and Neuroimmunology
Participating Journals
Frontiers in Immunology
- 5.7 impact factor
- 9.8 citescore
Impact
- 138kTopic views
- 108kArticle views
- 29kArticle downloads